Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

dovitinib (TKI258)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Novartis, Oncoheroes

Drug class:

FGFR inhibitor, VEGFR inhibitor, PDGFR inhibitor, pan-TRK inhibitor

Related drugs:

‹

lenvatinib (90)

erdafitinib (70)

infigratinib (53)

futibatinib (52)

pemigatinib (41)

BAY 1163877 (23)

Debio 1347 (17)

BAY 1179470 (0)

sunitinib (139)

fruquintinib (24)

surufatinib (7)

adAptVEGF-C adenoviral vector (0)

VEGFR1-1084 (0)

BAY 57- 9352 (0)

pegpleranib (0)

›

FGFR1 amplification	Breast Cancer	FGFR1 amplification	Breast Cancer	TKI258 Sensitive: C2 – Inclusion Criteria TKI258 Sensitive : C2	TKI258 Sensitive: C2 – Inclusion Criteria TKI258 Sensitive : C2
FGF3 amplification	Breast Cancer	FGF3 amplification	Breast Cancer	TKI258 Sensitive: C3 – Early Trials TKI258 Sensitive : C3	TKI258 Sensitive: C3 – Early Trials TKI258 Sensitive : C3
FGFR2 amplification	Breast Cancer	FGFR2 amplification	Breast Cancer	TKI258 Sensitive: C3 – Early Trials TKI258 Sensitive : C3	TKI258 Sensitive: C3 – Early Trials TKI258 Sensitive : C3
FGFR1 amplification	Lung Non-Small Cell Squamous Cancer	FGFR1 amplification	Lung Non-Small Cell Squamous Cancer	TKI258 Sensitive: C3 – Early Trials TKI258 Sensitive : C3	TKI258 Sensitive: C3 – Early Trials TKI258 Sensitive : C3
FGFR2-CCDC6 fusion	Cholangiocarcinoma	FGFR2-CCDC6 fusion	Cholangiocarcinoma	TKI258 Sensitive: D – Preclinical TKI258 Sensitive : D	TKI258 Sensitive: D – Preclinical TKI258 Sensitive : D
FGFR2 mutation	Endometrial Cancer	FGFR2 mutation	Endometrial Cancer	TKI258 Sensitive: D – Preclinical TKI258 Sensitive : D	TKI258 Sensitive: D – Preclinical TKI258 Sensitive : D
FGFR1 overexpression	Bladder Cancer	FGFR1 overexpression	Bladder Cancer	TKI258 Sensitive: D – Preclinical TKI258 Sensitive : D	TKI258 Sensitive: D – Preclinical TKI258 Sensitive : D
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	TKI258 Sensitive: D – Preclinical TKI258 Sensitive : D	TKI258 Sensitive: D – Preclinical TKI258 Sensitive : D
MPZL3 overexpression	Breast Cancer	MPZL3 overexpression	Breast Cancer	TKI258 Sensitive: D – Preclinical TKI258 Sensitive : D	TKI258 Sensitive: D – Preclinical TKI258 Sensitive : D